Michael Leapman

Nov 22, 2024 | newswise.com | Michael Leapman

Prostate cancer is the second most commonly diagnosed cancer in men (behind skin cancer), with varying levels of aggressiveness. It’s also the second leading cause of cancer death, behind only lung cancer. A new study led by Yale Cancer Center researchers at Yale School Medicine found a substantial increase in the adoption of active surveillance (AS) and watchful waiting (WW) treatment strategies over the past decade — an encouraging trend for men seeking less invasive treatment options.

Jun 14, 2024 | jamanetwork.com | Michael Leapman |Julian Ho |Yang Liu

Key PointsQuestion  Can transcriptomic profiling of prostate cancer be linked with clinical and administrative data to evaluate relevant disease outcomes? Findings  This cohort study linked 92 976 participants undergoing genomic classifier testing of prostate cancer biopsy and radical prostatectomy specimens with insurance claims, pharmacy records, and electronic health record data.

Jun 2, 2023 | urotoday.com | Michael Leapman

In an interview with Matthew Cooperberg, Michael Leapman discusses his research on the use of genomic tests and imaging in prostate cancer and the resulting national practice patterns. Leapman found significant regional variation in the utilization of these tests, with areas rich in urologists and prostate cancer care showing higher adoption rates. He also observed a correlation between increased testing and active surveillance.

May 24, 2023 | urologytimes.com | Michael Leapman

Case-Based Peer PerspectivesInvestigator Perspectives Medical World NewsPodcastsRapid ReadoutsSponsored MediaUrology Medical PerspectivesUTv VideosUroViewViewpointsVirtual Tumor Board

Feb 23, 2023 | onclive.com | Michael Leapman

Michael S. Leapman, MD, MHS, associate professor of urology, clinical program leader, Prostate & Urologic Cancers Program, Yale Cancer Center, discusses key factors that influence patient experiences with biopsy-based genomic testing during active surveillance for prostate cancer, and how to best address them in clinical practice.